India has approved the use of Johnson & Johnson’s single-dose COVID-19 vaccine in an emergency situation, bolstering the country’s overall efforts to combat coronavirus.
“India adds to its vaccination arsenal! In India, the single-dose COVID-19 vaccination from Johnson & Johnson has been approved for emergency use. India now possesses five EUA vaccinations, according to Union Health Minister Mansukh Mandaviya.
A supply arrangement with domestic vaccine producer Biological E Limited would bring the shot to India.
With the recent approval of Johnson & Johnson’s candidate, India has now granted Emergency Use Approval (EUA) to five Covid-19 vaccines in order to combat the pandemic, which has claimed over 4.27 lakh lives and infected roughly 3.19 crore people in India.
On August 5, the US pharmaceuticals behemoth John & Johnson applied to the Central Drug Standard Control Organization (CDSCO) for emergency use authorisation (EUA) for their single-shot vaccination.
The company made the EUA submission based on “top line” efficacy and safety data from the Phase-3 ENSEMBLE clinical study, according to a statement.
Across all of the regions studied, the single-dose Covid-19 vaccine was found to be 85 percent effective in preventing severe cases of coronavirus illness.
The Covishield, Covaxin, and Sputnik-V vaccinations have all been given out in India thus far. Cipla, a pharmaceuticals business located in Mumbai, has also been given permission to import the Moderna vaccine, which has a 95% efficiency rate against coronavirus sickness.
More than 50 crore individuals have been vaccinated against COVID-19 in India, marking a significant milestone in the country’s vaccine coverage.
